

Pharmacy and Therapeutics Committee Meeting July 23, 2024
Draft Minutes

Members Present:

Lisa Price Stevens, M.D.
Tim Jennings, Pharm.D.
Ira Bloomfield, M.D.
Megan Sarashinsky, Pharm.D.
Olugbenga Obasanjo, M.D.
Michele Thomas, Pharm.D. (for
Alexis Aplasca, M.D.)
Rachel M. Selby-Penczak, M.D.
Ericka Crouse Pharm.D.

DMAS Staff:

MaryAnn McNeil, R.Ph., Pharmacy Manager
JoeMichael T. Fusco, Pharm.D., MCO Pharmacy Compliance Manager
Rachel Cain, Pharm.D., Clinical Pharmacist
Usha Koduru, Counsel to the Board, Office of the Attorney General
Kiara M. Jasper, MHA, CPhT, Pharmacy Systems Administrator
Talisha Sheppard, Medical Support Specialist
Jeff Lunardi, Chief Deputy Director DMAS

Absent:

Lura Thompson, Pharm.D.
Sarah Melton, Pharm.D.
Carol Forster, M.D.
Angela Venuto-Ashton, M.D.
Fredrick Moeller, M.D.

Staff: Magellan Rx Management

David Damico, Pharm.BS, R.Ph., Director Clinical Account Services
Nancy Eldin, Pharm.D., Pharmacist Account Executive
Nina Bandali, Pharm.D., Rebate Account Executive, Rebate and PDL Jeni
Hodzic, CPhT, Senior Account Management Specialist

A quorum was present

Guests:

48 representatives from pharmaceutical companies, providers, advocates,
associations, etc.

Welcome and Comments from Lisa Price Stevens, M.D., Chief Medical Officer and Chairman: Dr.

Lisa Price Stevens called the meeting to order and welcomed the members of the Committee and thanked them for their participation in this P&T Meeting. After the introductions, with committee permission, Dr. Price-Stevens turned over chair duties to Dr. Tim Jennings.

Call to Order: The meeting was called to order by Dr. Jennings.

DMAS' Drug Utilization Review (DUR) Board Update: There has been no DUR meeting since the last P&T meeting on June 27th 2024.

The next DUR Board meeting is scheduled for September 12 2024.

The minutes from these meetings can be found at:

<https://www.virginiamedicaidpharmacyservices.com/provider/drug-utilization-review/>

Housekeeping: Dr. Jennings reminded the members of the conflict-of-interest statement requirements and that the by-laws will be include in all future P&T materials. He informed the committee that Magellan will be presenting an overview of the drugs.

PDL Management

1. **Endocrine and Metabolic Agents Weight Management Agents (Closed Class):**

Speaker

- Sonya Raiker MS, MPH Associate Director, Outcomes Liasons Value, Evidence and Outcomes Eli Lilly (Zepbound™)

Dr. D'Amico presented the Weight Management Agents clinical information. A motion was made and seconded and the committee voted unanimously for this class to continue to be PDL eligible.

Comments from the Office of the Attorney General

Ms. Usha Koduru from the Attorney General's office stated that under the Virginia Freedom of Information Act (FOIA), specifically Virginia Code section 2.2-3711, a public body such as the P&T Committee, may go into a closed session for any one of the 51 reasons listed in that statute. The discussion of manufacturer and wholesaler prices is not one of the 51 reasons listed.

She stated the Attorney General strongly supports the principles of open government embodied by the FOIA and believes in the opportunity of the Commonwealth's citizens to fully witness the operation of government.

Federal Law 42 U.S.C. 1396r-8(b) (3) (D) requires such pricing information to be kept confidential. On this point, federal law supersedes the Virginia FOIA. Since the P&T Committee must discuss this pricing information as part of its duties, pursuant to federal law a confidential meeting must occur for the consideration of this pricing information, and she cautioned only this confidential pricing information should be discussed.

Dr. Tim Jennings made a motion for the P&T Committee to resume the meeting in another room to discuss this confidential information regarding prices charged by the manufacturers and wholesalers of the drug classes discussed at this P&T Committee meeting. This confidential meeting is authorized by Federal Law at 42 U.S.C. § 1396r-8(b) (3) (D) that requires this information be kept confidential. We are also going into closed session to request legal advice on the proposed Bylaws pursuant to Virginia code 2.2-3711 8B.

The motion was seconded and unanimously approved by the Committee.

Following the Confidential Session, the Committee members re-assembled on the public session. Dr. Jennings confirmed that to the best of each of the Committee member's knowledge the only information discussed at the confidential meeting was information regarding prices charged by the manufacturers and wholesalers of the drug classes discussed at this P&T Committee meeting as well as legal advice pertaining to the bylaws. As authorized by Federal Law at 42 U.S.C. § 1396r-8(b) (3) (D) that requires this information to be kept confidential.

A motion was made to resume the meeting and for the members to approve the confidential session statement. The motion was seconded and unanimously approved by the Committee.

PDL Changes Effective August 9, 2024

Ad Hoc Meeting Review

Dr. Jennings made the following motions that were seconded and approved unanimously by the Committee (note the motions are for changes to the current PDL status):

1. **Weight Management Agents (Closed Class)**: Saxenda® and Wegovy® are nonpreferred.

Clinical Criteria and Service Authorization (SA) Forms

The Committee members reviewed the proposed new or revised clinical criteria, including new and updated service authorization fax forms. A Committee member made the following motion to approve new or revised clinical criteria for the following drugs and drug classes, which was seconded and approved unanimously by the Committee:

- New criteria and SA form for Adult Weight Management Agents with revisions requested by the board members
- New criteria and SA form for Wegovy for Cardiovascular Risk Reduction with revisions requested by the board members

Closing Comments:

The next P&T Committee Meeting is scheduled for October 8, 2024. A motion to adjourn the meeting was made and seconded. After a unanimous vote, Dr. Jennings adjourned the meeting.